Using the system to deliver a combinatorial gene of interleukin 6 short hairpin RNA (IL-6 shRNA) and CD19 CAR, they successfully transformed T-cells into IL-6 downregulated CAR-T-cells, which killed leukemic tumor cells with high CD19 expression while reducing the CRS caused by IL-6. Here, CD19 is linked to neoplasm.